Corrigendum to “Central vasopressin V1a receptors modulate neural processing in mothers facing intruder threat to pups” [Neuropharmacology 58 (2010) 107–116]

Abstract

The authors of the above paper regret that the incorrect name was given for the V1a receptor antagonist drug that was administered to rats before MRI experiments. The correct name for the drug is [β-Mercapto-β,β-cyclopentamethylenepropionyl1, O-me-Tyr2,Arg8]-Vasopressin (commercially available through Sigma-Aldrich, St. Louis, MO; Product #V2255) and was not [deamino-Pen(1), O-Me-Tyr, Arg(8)]-Vasopressin. The incorrect name was for a nonselective V1 receptor antagonist that was not used in the study.